CTLA4 and cancer: Strategies under investigation include combining ICIs with immunogenic cell death inducers [40]; targeting innate immune checkpoints [41]; and integrating mRNA-based cancer vaccines with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies [42].